Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors

Схожие документы

• Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
  по: Chatrath, Ajay, et al.
  Опубликовано: (2021)
• The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
  по: Nan, Zhang, et al.
  Опубликовано: (2021)
• Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma
  по: Fangshi Xu, et al.
  Опубликовано: (2022-05-01)
• The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
  по: Yongfeng Wu, et al.
  Опубликовано: (2019-11-01)
• The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
  по: Wu, Yongfeng, et al.
  Опубликовано: (2019)